ARID1A and hepatocellular carcinoma: In HCC, several studies have shown recurrent mutations at TP53, CTNNB1, AXIN1, IRF2, CDKN1A, CDKN2A, ARID1A, ARID2, and TERT, which have been addressed to promote HCC development and/or progression implicating clinical outcomes [9–14].